title: The management of neonatal pulmonary hypertension.
abstract: Most neonates with clinically significant pulmonary hypertension (PH) will have either persistent PH of the newborn (PPHN) or bronchopulmonary dysplasia. Cyanotic congenital heart disease must be actively ruled out as part of the differential diagnosis of PPHN. The maintenance of ductal patency with prostaglandins E1 or E2 in cases of doubt is safe and potentially beneficial given their pulmonary vasorelaxant properties. Specific tools in the treatment of PPHN include modern ventilatory strategies, inhaled nitric oxide, sildenafil, prostacyclin and extracorporeal membrane oxygenation. Rarely will a cardiac lesion be primarily responsible for neonatal PH although pulmonary vein stenosis and the persistence of an arterial duct must be considered, particularly in the older preterm baby with bronchopulmonary dysplasia.
authors.affiliation: Department of Cardiac Services, Birmingham Children's Hospital, UK. rami.dhillon@bch.nhs.uk
authors.forename: Rami
authors.initials: R
authors.lastname: Dhillon
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001997:Bronchopulmonary Dysplasia / Q000150:complications; D015199:Extracorporeal Membrane Oxygenation; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000175:diagnosis / Q000628:therapy
chemical_list: D000959:Antihypertensive Agents